Materials
& METHODS
Animals
Adult male Sprague-Dawley rats (Envigo, Indianapolis, IN; PND >60; 320-450 g
at the start of the experiment) were individually housed in a temperature-controlled
vivarium with ad libitum access (except where noted) to water and food (LabDiet 5001,
LabDiet, St. Louis, MO) on a 12h:12h reverse light/dark cycle. All procedures were
approved by the Institute of Animal Care and Use Committee at the University of
Southern California.
Surgery
For all surgical procedures, rats were anesthetized and sedated via intramuscular
injections of ketamine (90 mg/kg), xylazine (2.8 mg/kg), and acepromazine (0.72
mg/kg). Rats were also given analgesic (subcutaneous injection of ketoprofen [5
mg/kg]) after surgery and once daily for 3 subsequent days thereafter. All rats recovered
for at least one-week post-surgery prior to experimental procedures.
Intracranial cannula implantation for drug delivery
For pharmacological delivery into the lateral ventricle (LV) for
intracerebroventricular (ICV) drug (clozapine N-oxide [CNO]) administration, rats were
surgically implanted with a unilateral indwelling guide cannula (26-gauge, Plastics One,
Roanoke, VA) using the stereotaxic coordinates, relative to the location of bregma: -0.90
mm anterior/posterior (AP), +1.80 mm medial/lateral (ML), and -2.60 mm
dorsal/ventral (DV) with the DV coordinate zeroed at the surface of the skull before
being lowered into the brain. Cannula were affixed to the skull as previously described
using jeweler’s screws and dental cement [26]. Following a week of recovery, the
optimal injector tip length for infusion into the LV was determined by injecting 5-Thio-
D-Glucose (5-TG) (Sigma-Aldrich, St. Louis MO) into the LV and measuring change in
blood glucose. Rats were mildly food restricted before 5-TG testing [27]. An initial blood
glucose reading was taken an hour after the dark cycle onset using a OneTouch monitor
with blood taken from the tip of the tail from a small cut by a sterile razor blade. Starting
with an injector that extends 2.0 mm beyond the end of the guide cannula, 2 uL of a 105
mg/mL 5-TG solution was then infused into the LV using a Hamilton microinjector.
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
Blood glucose readings were taken 30 min and 1 hr following infusion of 5-TG. An
animal was considered to pass with a given tip length targeting the ventricle if their
blood glucose approximately doubled in that time. The procedure was repeated on
subsequent days as needed for an animal with injector tip lengths of 2.50 mm and 3.00
mm until the animal passed. This passing tip length was then used for all subsequent
ICV drug deliveries.
Intracranial virus injection
Stereotaxic injections of viruses were delivered using a micro-infusion pump
(Harvard Apparatus, Cambridge, MA, USA) connected to a 26-gauge microsyringe
injector attached to a PE20 catheter and 10 µL Hamilton syringe. The flow rate was
calibrated and set to 5 µL/min. The volume of each viral infusion was 300 nL and
injectors were left in place for 2 min post-infusion. Following viral infusions, animals
were either implanted with indwelling LV ICV cannula as described above, or surgically
closed with sutures. Experiments occurred starting 3 weeks after viral injection to allow
for virus transduction and expression. Successful expression was confirmed postmortem
in animals via immunohistochemistry (IHC) staining as described below. All OTp-
driven viruses were produced and validated by Dr. Valery Grinevich’s laboratory at the
Central Institute of Mental Health, University of Heidelberg, Germany.
For chemogenetic activation of OT neurons via DREADDs (Figure 1A) an
AAV1/2_OTp_hM3D(Gq)-mcherry (OTp DREADDs; [28]) was bilaterally injected to
target regions at the following coordinates: paraventricular hypothalamus (PVH) -1.80
mm AP, +/-0.35 mm ML, -8.0 mm DV; and supraoptic nuclei (SON) -1.10 mm AP, +/-
1.80 mm ML, -9.20 mm DV (0 reference point for AP, ML and DV at bregma).
Representative photomicrographs of OTp DREADDs viral expression in each region are
shown in Figure 1B.
Synaptic silencing of vesicular release of OT was accomplished using
AAV1/2_OTp_TTLC-ko_WPRE (OTp TTLC; [29]) virus to express the tetanus-toxin
light chain (TTLC) protein which cleaves vesicle-associated membrane protein
synaptobrevin to prevent vesicle fusion and release (Figure 1C). Additionally, this virus
expresses a koomassi orange (ko) fluorescent reporter protein that can be visualized
under a fluorescent microscope. This virus was targeted to PVH and SON regions using
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
the same coordinates listed above. Representative photomicrographs of OTp TTLC viral
expression in each region is shown in Figure 1D.
To control for effects of viral infusions, we used an OT promoter virus absent
DREADDs or TTLC constructs (AAV1/2_OTp_Venus; [30]) as a control virus which
drives the expression of the yellow fluorescent protein Venus selectively in OT neurons
[31].
Immunohistochemistry (IHC) and microscopy
Rats were anesthetized and sedated via intramuscular injections of ketamine
(90.1 mg/kg)/xylazine (2.8 mg/kg)/acepromazine (0.72 mg/kg) cocktail, then
transcardially perfused with 0.9% sterile saline (pH 7.4) followed by 4%
paraformaldehyde (PFA) in 0.1M borate buffer (pH 9.5). Brains were dissected out and
post-fixed in PFA with 12% sucrose for 24 h, then flash-frozen in isopentane cooled in
dry ice. Brains were sectioned to 30-μm thickness on a freezing microtome and sections
were collected and stored in antifreeze solution at −20°C until further processing.
The following IHC fluorescence labeling procedures were adapted from previous
work [32]. Guinea pig anti-Oxytocin-neurophysin 1 (1:10,000 dilution; Abcam,
Cambridge, United Kingdom; Catalog #:ab228508, Lot #:GR3357270-1; Clonality:
Polyclonal) and rabbit anti-RFP (1:2000 dilution, Rockland Inc., Limerick, PA, USA;
Catalog #:600-401-379; Clonality: Polyclonal) were the two antibodies used. Antibodies
were prepared in 0.02M potassium phosphate-buffered saline (KPBS) solution
containing 0.2% sodium azide and 2.0% normal donkey serum and stored at 4C
overnight. After a series of six washes with 0.02M KPBS, brain sections were incubated
in a secondary antibody solution. The two secondary antibodies used, donkey anti-
rabbit CyTM3 (Catalog #:711-165-152) and donkey anti-guinea pig Alexa Fluor (AF) 488
(Catalog #:706-545-148) had a 1:500 dilution and were stored overnight at 4 °C
(Jackson ImmunoResearch; West Grove, PA, USA). Sections were then mounted and
cover-slipped with using 50% glycerol in 0.02M KPBS and clear nail polish was used to
seal the coverslip onto the slide.
Antibody tagging of OT first involved washing the brain sections on a motorized
rotating platform in the following order (overnight incubations on a motorized rotating
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
platform at 4C): (1) 0.02M KPBS (changing KPBS every 5 min for 30 min), (2) 0.3%
Triton X-100 in KPBS (30 min), (3) KPBS (changing KPBS every 5 min for 15 min), (4)
2% donkey serum in KPBS (10 min), (5) 2% normal donkey serum, 0.2% sodium azide,
and guinea pig anti-OT [1:10,000; guinea pig anti-OT] and rabbit anti-RFP [1:2000;
rabbit anti-RFP] in KPBS (24 h), (6) KPBS (changing KPBS every 10 min for 1 h), (7) 2%
normal donkey serum, 0.2% sodium azide and secondary antibodies (1:500; donkey
anti-guinea pig AF488 and donkey anti-rabbit Cy3; overnight) in KPBS (30 h), (8) KPBS
(changing KPBS every 2 min for 4 min). Photomicrographs were acquired using a Nikon
80i (Nikon DS-QI1,1280 x 1024 resolution, 1.45 megapixel) microscope under
epifluorescence.
Characterization of OT DREADDs and TTLC expression
For OT DREADDs experiments, immunostaining for RFP to amplify the mCherry
signal and label OT neurons was conducted as described above. Counts were performed
in sections from the Swanson Brain Atlas levels 22-27, which encompasses OT-
containing neurons in the PVH and SON, for colocalization of OT and fluorescence
reporter for OT DREADDs. For OT DREADDs experiments, animals were excluded from
analysis if fewer than 40% of the total number of OT neurons were transduced with RFP
(based on IHC staining for OT). All animals that met this criterion were included for
experimental analysis. The percentage of OT that express the viral DREADDs marker (#
expressing RFP/# total immunoreactive OT neurons) for the PVH was: Mean = 0.7603,
SEM = 0.0331, SD = 0.119. For the SON, the percentage was: Mean = 0.7262, SEM =
0.0143, SD = 0.0757.
For OT neuron synaptic silencing (TTLC) experiments IHC was performed as
described above to label OT neurons using a green fluorescent protein. Counts were
performed in sections from the Swanson Brain Atlas levels 22-27, which encompasses
OT-containing neurons in the PVH and SON, for colocalization of OT neurons and
fluorescence reporter for OT TTLC virus which consisted of a kusabira orange (KO)
protein that could be visualized using the TRITC filter on the microscope. For OT
neuron silencing experiments, animals were excluded from analysis if fewer than 40% of
the total number of OT neurons were transduced with kusabira orange. All animals that
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
met this criterion were included for experimental analysis. Experimenters performing
the counting were blind to experimental assignments. The percentage of OT that express
the viral TTLC marker (# expressing KO/# total immunoreactive OT neurons) for the
PVH was: Mean = 0.598, SEM = 0.081, SD = 0.244. For the SON, the percentage was
Mean = 0.7644, SEM = 0.044, SD = 0.1538.
Drug preparation
For chemogenetic activation of OT neurons, 2 µL (18 mM/2 µL) CNO or vehicle
daCSF (33% DMSO in 66% aCSF) is administered ICV through a microsyringe
connected to an injector tip. Injector tip was left in place for 30 seconds before removal
and any instances of backflow from the cannula upon injector removal were noted.
Doses of CNO and vehicle were based on previous work [32; 33]. Prior to drug injections
animals were handled and prepared for injections. Injections of CNO or vehicle occurred
45-60 min prior to the start of measuring feeding behavior.
Caloric intake studies
Animals were housed in a reverse light/dark cycle (lights off at 11:00 a.m.). Home
cages were integrated in a BioDAQ food monitoring intake system to which they were
habituated to for at least 5 days prior to any treatments. For pharmacological
experiments on test days, home cage food access was removed 1 h prior to dark onset.
For chemogenetic activation of OT neurons, drug treatments were counterbalanced
across animals using a within-subject design. Infusions of CNO or daCSF occurred 45-
60 min prior to the start of the dark cycle, at which point access to food was restored
and food intake parameters were recorded for the subsequent 6 h. Drug treatments were
separated by 2 days.
Chow experiments were conducted with animals maintained on ad libitum chow
(LabDiet 5001, LabDiet, St. Louis, MO) housed within the BioDAQ system.
Chemogenetic activation experiments consisted of two treatment days separated by two
intervening washout days where chow intake was recorded from the onset of the dark
cycle. For chronic silencing experiments animals were maintained on chow for a period
of habituation as well as for recording 5 consecutive days of meal patterns starting at the
onset of the dark cycle that were averaged together. High fat high sugar diet (HFHS)
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
experiments were conducted using a 45 kcal% fat diet (Research Diets Inc. New
Brunswick, NJ; Catalog #: D12451) which the animals were habituated to and
maintained on for at least 5 days prior to test days or recording. For sucrose
experiments animals received two habituation days to a 11% weight by volume sucrose
solution (colored with blue food dye) with 2 h access to sucrose solution in their home
cage using a liquid BioDAQ monitor. Habituation was followed by two test days that
recorded sucrose intake for 2 h starting at the onset of the dark cycle, during which time
regular food was not available.
For analysis of BioDAQ data for chow and HFHS conditions an inter-meal
interval (IMI) of 900 s was used to separate individual eating bouts into separate meals.
Data was binned into 12 bins of 30 min each which were used to calculate values for
each of the time points depicted for DREADDs experiments (0.5 h, 1 h, 2 h, 4 h, 6 h).
Intake parameters were only evaluated for up to 6 h for DREADDs experiments based
on the half-life of CNO, as well as previous results from our lab in which CNO-mediated
effects on food intake did not extend beyond 6 h using a similar food intake
experimental design [32-34]. For chronic silencing experiments data was extracted for
each day of a 5-day period and then averaged together to get final values. Sucrose tests
were analyzed with a 300 sec (5 min) IMI to separate liquid sucrose meals [35], and the
test only occurred for 2 h total length with data binned into 30 min intervals.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 10.3.1 software
(GraphPad Software Inc., San Diego, CA, USA). Data are expressed as mean +/- SEM.
Statistical test details can be found in the figure legends and “n’s” refers to the number
of animals for each condition. Significance was considered at p<0.05.
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
References
[1] Grinevich, V., Knobloch-Bollmann, H.S., Eliava, M., Busnelli, M., Chini, B., 2016.
Assembling the Puzzle: Pathways of Oxytocin Signaling in the Brain. Biological Psychiatry
79(3):155-164.
[2] Lee, H.J., Macbeth, A.H., Pagani, J.H., Young, W.S., 3rd, 2009. Oxytocin: the great
facilitator of life. Prog Neurobiol 88(2):127-151.
[3] Buijs, R.M., Swaab, D.F., Dogterom, J., van Leeuwen, F.W., 1978. Intra- and
extrahypothalamic vasopressin and oxytocin pathways in the rat. Cell Tissue Res
186(3):423-433.
[4] Jurek, B., Neumann, I.D., 2018. The Oxytocin Receptor: From Intracellular Signaling
to Behavior. Physiological Reviews 98(3):1805-1908.
[5] Onaka, T., Takayanagi, Y., 2019. Role of oxytocin in the control of stress and food
intake. J Neuroendocrinol 31(3):e12700.
[6] Raam, T., McAvoy, K.M., Besnard, A., Veenema, A.H., Sahay, A., 2017. Hippocampal
oxytocin receptors are necessary for discrimination of social stimuli. Nature
Communications 8(1):2001.
[7] Liu, C.M., Spaulding, M.O., Rea, J.J., Noble, E.E., Kanoski, S.E., 2021. Oxytocin and
Food Intake Control: Neural, Behavioral, and Signaling Mechanisms. Int J Mol Sci 22(19).
[8] Maejima, Y., Iwasaki, Y., Yamahara, Y., Kodaira, M., Sedbazar, U., Yada, T., 2011.
Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat
mass. Aging (Albany NY) 3(12):1169-1177.
[9] Ott, V., Finlayson, G., Lehnert, H., Heitmann, B., Heinrichs, M., Born, J., et al., 2013.
Oxytocin reduces reward-driven food intake in humans. Diabetes 62(10):3418-3425.
[10] Kerem, L., Hadjikhani, N., Holsen, L., Lawson, E.A., Plessow, F., 2020. Oxytocin
reduces the functional connectivity between brain regions involved in eating behavior in
men with overweight and obesity. Int J Obes (Lond) 44(5):980-989.
[11] Arletti, R., Benelli, A., Bertolini, A., 1990. Oxytocin inhibits food and fluid intake in
rats. Physiol Behav 48(6):825-830.
[12] Ong, Z.Y., Bongiorno, D.M., Hernando, M.A., Grill, H.J., 2017. Effects of Endogenous
Oxytocin Receptor Signaling in Nucleus Tractus Solitarius on Satiation-Mediated Feeding
and Thermogenic Control in Male Rats. Endocrinology 158(9):2826-2836.
[13] Ong, Z.Y., Alhadeff, A.L., Grill, H.J., 2015. Medial nucleus tractus solitarius oxytocin
receptor signaling and food intake control: the role of gastrointestinal satiation signal
processing. Am J Physiol Regul Integr Comp Physiol 308(9):R800-806.
[14] Thienel, M., Fritsche, A., Heinrichs, M., Peter, A., Ewers, M., Lehnert, H., et al., 2016.
Oxytocin's inhibitory effect on food intake is stronger in obese than normal-weight men. Int
J Obes (Lond) 40(11):1707-1714.
[15] Morton, G.J., Thatcher, B.S., Reidelberger, R.D., Ogimoto, K., Wolden-Hanson, T.,
Baskin, D.G., et al., 2012. Peripheral oxytocin suppresses food intake and causes weight
loss in diet-induced obese rats. Am J Physiol Endocrinol Metab 302(1):E134-144.
[16] Blevins, J.E., Thompson, B.W., Anekonda, V.T., Ho, J.M., Graham, J.L., Roberts, Z.S.,
et al., 2016. Chronic CNS oxytocin signaling preferentially induces fat loss in high-fat diet-
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
fed rats by enhancing satiety responses and increasing lipid utilization. Am J Physiol Regul
Integr Comp Physiol 310(7):R640-658.
[17] Niu, J., Tong, J., Blevins, J.E., 2021. Oxytocin as an Anti-obesity Treatment. Front
Neurosci 15:743546.
[18] Olszewski, P.K., Noble, E.E., Paiva, L., Ueta, Y., Blevins, J.E., 2022. Oxytocin as a
potential pharmacological tool to combat obesity. J Neuroendocrinol 34(9):e13106.
[19] Plessow, F., Marengi, D.A., Perry, S.K., Felicione, J.M., Franklin, R., Holmes, T.M., et
al., 2018. Effects of Intranasal Oxytocin on the Blood Oxygenation Level-Dependent Signal
in Food Motivation and Cognitive Control Pathways in Overweight and Obese Men.
Neuropsychopharmacology 43(3):638-645.
[20] Son, S., Manjila, S.B., Newmaster, K.T., Wu, Y.T., Vanselow, D.J., Ciarletta, M., et al.,
2022. Whole-Brain Wiring Diagram of Oxytocin System in Adult Mice. J Neurosci
42(25):5021-5033.
[21] Althammer, F., Grinevich, V., 2017. Diversity of oxytocin neurons: beyond magno-
and parvocellular cell types? J Neuroendocrinol.
[22] Grill, H.J., Hayes, M.R., 2012. Hindbrain neurons as an essential hub in the
neuroanatomically distributed control of energy balance. Cell Metab 16(3):296-309.
[23] Klockars, A., Levine, A.S., Olszewski, P.K., 2015. Central oxytocin and food intake:
focus on macronutrient-driven reward. Front Endocrinol (Lausanne) 6:65.
[24] Miedlar, J.A., Rinaman, L., Vollmer, R.R., Amico, J.A., 2007. Oxytocin gene deletion
mice overconsume palatable sucrose solution but not palatable lipid emulsions. Am J
Physiol Regul Integr Comp Physiol 293(3):R1063-1068.
[25] Olszewski, P.K., Klockars, A., Olszewska, A.M., Fredriksson, R., Schiöth, H.B.,
Levine, A.S., 2010. Molecular, immunohistochemical, and pharmacological evidence of
oxytocin's role as inhibitor of carbohydrate but not fat intake. Endocrinology 151(10):4736-
4744.
[26] Liu, C.M., Davis, E.A., Suarez, A.N., Wood, R.I., Noble, E.E., Kanoski, S.E., 2020. Sex
Differences and Estrous Influences on Oxytocin Control of Food Intake. Neuroscience
447:63-73.
[27] Slusser, P.G., Ritter, R.C., 1980. Increased feeding and hyperglycemia elicited by
intracerebroventricular 5-thioglucose. Brain Research 202(2):474-478.
[28] Grund, T., Tang, Y., Benusiglio, D., Althammer, F., Probst, S., Oppenländer, L., et al.,
2019. Chemogenetic activation of oxytocin neurons: Temporal dynamics, hormonal
release, and behavioral consequences. Psychoneuroendocrinology 106:77-84.
[29] Grinevich, V., Knobloch-Bollmann, H.S., Roth, L.C., Althammer, F., Domanskyi, A.,
Vinnikov, I.A., et al., 2016. Somatic Transgenesis (Viral Vectors). Molecular
Neuroendocrinology, p. 243-274.
[30] Knobloch, H.S., Charlet, A., Hoffmann, L.C., Eliava, M., Khrulev, S., Cetin, A.H., et
al., 2012. Evoked axonal oxytocin release in the central amygdala attenuates fear
response. Neuron 73(3):553-566.
[31] Knobloch, H.S., Charlet, A., Hoffmann, Lena C., Eliava, M., Khrulev, S., Cetin, Ali H.,
et al., 2012. Evoked Axonal Oxytocin Release in the Central Amygdala Attenuates Fear
Response. Neuron 73(3):553-566.
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
[32] Terrill, S.J., Subramanian, K.S., Lan, R., Liu, C.M., Cortella, A.M., Noble, E.E., et al.,
2020. Nucleus accumbens melanin-concentrating hormone signaling promotes feeding in
a sex-specific manner. Neuropharmacology 178:108270.
[33] Noble, E.E., Hahn, J.D., Konanur, V.R., Hsu, T.M., Page, S.J., Cortella, A.M., et al.,
2018. Control of Feeding Behavior by Cerebral Ventricular Volume Transmission of
Melanin-Concentrating Hormone. Cell Metab 28(1):55-68.e57.
[34] Jendryka, M., Palchaudhuri, M., Ursu, D., van der Veen, B., Liss, B., Kätzel, D., et al.,
2019. Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine,
and compound 21 in DREADD-based chemogenetics in mice. Scientific Reports 9(1):4522.
[35] Spector, A.C., Klumpp, P.A., Kaplan, J.M., 1998. Analytical issues in the evaluation
of food deprivation and sucrose concentration effects on the microstructure of licking
behavior in the rat. Behav Neurosci 112(3):678-694.
[36] Kerem, L., Lawson, E.A., 2021. The Effects of Oxytocin on Appetite Regulation, Food
Intake and Metabolism in Humans. International Journal of Molecular Sciences
22(14):7737.
[37] Rea, J.J., Liu, C.M., Hayes, A.M.R., Bashaw, A.G., Schwartz, G.M., Ohan, R., et al.,
2024. Hippocampus Oxytocin Signaling Promotes Prosocial Eating in Rats. Biol Psychiatry.
[38] Althammer, F., Roy, R.K., Lefevre, A., Najjar, R.S., Schoenig, K., Bartsch, D., et al.,
2022. Altered PVN-to-CA2 hippocampal oxytocin pathway and reduced number of
oxytocin-receptor expressing astrocytes in heart failure rats. Journal of
neuroendocrinology 34(7):e13166.
[39] Althammer, F., Eliava, M., Grinevich, V., 2021. Chapter 3 - Central and peripheral
release of oxytocin: Relevance of neuroendocrine and neurotransmitter actions for
physiology and behavior. In: Swaab, D.F., Kreier, F., Lucassen, P.J., Salehi, A., Buijs, R.M.,
editors. Handbook of Clinical Neurology. Elsevier, p. 25-44.
[40] Grinevich, V., Neumann, I.D., 2021. Brain oxytocin: how puzzle stones from animal
studies translate into psychiatry. Mol Psychiatry 26(1):265-279.
[41] Eliava, M., Melchior, M., Knobloch-Bollmann, H.S., Wahis, J., da Silva Gouveia, M.,
Tang, Y., et al., 2016. A New Population of Parvocellular Oxytocin Neurons Controlling
Magnocellular Neuron Activity and Inflammatory Pain Processing. Neuron 89(6):1291-
1304.
[42] Tang, Y., Benusiglio, D., Lefevre, A., Hilfiger, L., Althammer, F., Bludau, A., et al.,
2020. Social touch promotes interfemale communication via activation of parvocellular
oxytocin neurons. Nat Neurosci 23(9):1125-1137.
[43] Hasan, M.T., Althammer, F., Silva da Gouveia, M., Goyon, S., Eliava, M., Lefevre, A.,
et al., 2019. A Fear Memory Engram and Its Plasticity in the Hypothalamic Oxytocin
System. Neuron 103(1):133-146.e138.
[44] Lefevre, A., Benusiglio, D., Tang, Y., Krabichler, Q., Charlet, A., Grinevich, V., 2021.
Oxytocinergic Feedback Circuitries: An Anatomical Basis for Neuromodulation of Social
Behaviors. Front Neural Circuits 15:688234.
[45] Lord, M.N., Subramanian, K., Kanoski, S.E., Noble, E.E., 2021. Melanin-
concentrating hormone and food intake control: Sites of action, peptide interactions, and
appetition. Peptides 137:170476.
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
[46] Subramanian, K.S., Lauer, L.T., Hayes, A.M.R., Décarie-Spain, L., McBurnett, K.,
Nourbash, A.C., et al., 2023. Hypothalamic melanin-concentrating hormone neurons
integrate food-motivated appetitive and consummatory processes in rats. Nature
Communications 14(1):1755.
[47] Sanathara, N.M., Garau, C., Alachkar, A., Wang, L., Wang, Z., Nishimori, K., et al.,
2018. Melanin concentrating hormone modulates oxytocin-mediated marble burying.
Neuropharmacology 128:22-32.
[48] Yao, Y., Fu, L.Y., Zhang, X., van den Pol, A.N., 2012. Vasopressin and oxytocin excite
MCH neurons, but not other lateral hypothalamic GABA neurons. Am J Physiol Regul Integr
Comp Physiol 302(7):R815-824.
[49] Rossi, M., Beak, S.A., Choi, S.J., Small, C.J., Morgan, D.G.A., Ghatei, M.A., et al.,
1999. Investigation of the feeding effects of melanin concentrating hormone on food intake
- Action independent of galanin and the melanocortin receptors. Brain Research
846(2):164-170.
[50] Huber, D., Veinante, P., Stoop, R., 2005. Vasopressin and oxytocin excite distinct
neuronal populations in the central amygdala. Science 308(5719):245-248.
[51] Lin, Y.T., Hsieh, T.Y., Tsai, T.C., Chen, C.C., Huang, C.C., Hsu, K.S., 2018.
Conditional Deletion of Hippocampal CA2/CA3a Oxytocin Receptors Impairs the
Persistence of Long-Term Social Recognition Memory in Mice. J Neurosci 38(5):1218-1231.
[52] Ludwig, M., Leng, G., 2006. Dendritic peptide release and peptide-dependent
behaviours. Nat Rev Neurosci 7(2):126-136.
[53] Wang, X., Escobar, J.B., Mendelowitz, D., 2021. Sex Differences in the Hypothalamic
Oxytocin Pathway to Locus Coeruleus and Augmented Attention with Chemogenetic
Activation of Hypothalamic Oxytocin Neurons. Int J Mol Sci 22(16).
[54] Asarian, L., Geary, N., 2013. Sex differences in the physiology of eating. Am J Physiol
Regul Integr Comp Physiol 305(11):R1215-1267.
[55] Gabor, C.S., Phan, A., Clipperton-Allen, A.E., Kavaliers, M., Choleris, E., 2012.
Interplay of oxytocin, vasopressin, and sex hormones in the regulation of social
recognition. Behav Neurosci 126(1):97-109.
[56] Dumais, K.M., Veenema, A.H., 2016. Vasopressin and oxytocin receptor systems in
the brain: Sex differences and sex-specific regulation of social behavior. Frontiers in
Neuroendocrinology 40:1-23.
[57] Caldwell, H.K., 2017. Oxytocin and Vasopressin: Powerful Regulators of Social
Behavior. Neuroscientist 23(5):517-528.
[58] Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., et al., 2012.
Oxytocin and vasopressin agonists and antagonists as research tools and potential
therapeutics. J Neuroendocrinol 24(4):609-628.
[59] Chini, B., Manning, M., 2007. Agonist selectivity in the oxytocin/vasopressin
receptor family: new insights and challenges. Biochem Soc Trans 35(Pt 4):737-741.
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
Supplemental Figure 1.
0 2 3 4 5 7 9 111416182123252830323334353637394244464951535658606365677072
250
300
350
400
450
500
Days Since Surgery
Bodyweight (g)
CON
PVH Silenced
SON Silenced
2 3 4 5 7 9 111416182123252830323334353637394244464951535658606365677072
-50
0
50
100
150
200
Days Since Surgery
Change in Bodyweight (g)
CON
PVH Silenced
SON Silenced
A
B
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
Supplemental Figure 1. Changes in bodyweight following the expression of
OTp TTLC to chronically silence synaptic transmission from OT neurons.
(A) There were no differences in average bodyweights between groups following the
expression of OTp in either the PVH or SON. (B) No differences were seen in the
average change in bodyweight following chronic synaptic silencing of OT neurons in
either the PVH or SON compared to controls.
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
0.5 h 1 h 1.5 h 2 h
0
5
10
15
20Total Sucrose Intake (kcal)
daCSF
CNO
0.5 h 1 h 1.5 h 2 h
0
2
4
6
8Number of Sucrose Meals
daCSF
CNO
0.5 h 1 h 1.5 h 2 h
0
5
10
15Avg Sucrose Meal Size (kcal)
daCSF
CNO
0.5 h 1 h 2 h 4 h 6 h
0
20
40
60
80Total Chow Intake (kcal)
daCSF
CNO
0.5 h 1 h 2 h 4 h 6 h
0
2
4
6Number of Chow Meals
daCSF
CNO
0.5 h 1 h 2 h 4 h 6 h
0
10
20
30
40Avg Chow Meal Size (kcal)
daCSF
CNO
0.5 h 1 h 2 h 4 h 6 h
0
20
40
60Total HFHS Intake (kcal)
daCSF
CNO
0.5 h 1 h 2 h 4 h 6 h
0
2
4
6
8Number of HFHS Meals
daCSF
CNO
✱
0.5 h 1 h 2 h 4 h 6 h
0
10
20
30
40Avg HFHS Meal Size (kcal)
daCSF
CNO
Supplemental Figure 2.
A B C
D E F
G H I
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint
Supplemental Figure 2. Lateral ventricle infusion of CNO has no effects on
food intake. (A-C) ICV administration of CNO in animals with control virus
(anterograde tracer, not DREADDs) had no effect on cumulative chow intake, chow
meal frequency or average chow meal size. (D-F) ICV administration of CNO had no
effect on cumulative HFHS intake or average HFHS meal size, though there was a
transient increase in HFHS meal frequency at 2 hr (t(6)=2.828, p=0.03). (G-I) CNO
administration in control animals had no effect on cumulative sucrose intake, liquid
sucrose meal frequency or average liquid sucrose meal size. (CNO Control: chow=7,
sucrose=8, HFHS=7; all within-subjects design for drug treatments; Data are means ±
SEM; *p<0.05).
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
The copyright holder for this preprintthis version posted November 21, 2024. ; https://doi.org/10.1101/2024.11.20.624599doi: bioRxiv preprint